SINGAPORE, May 27, 2018 /PRNewswire/ -- Lion TCR Pte Ltd, a
clinical stage biotech pioneering T cell therapy against viral-
related cancer, announced today they have raised US$ 20 million in its Series A financing round.
The money raised is led primarily by undisclosed existing investors
and other new investors such as Yashang Capital and Westlake
Ventures Capital.
The proceeds from this fundraising will be primarily used to
advance its on-going clinical trials of its lead candidate
LioCyx™ (personalized HBV specific TCR T cell therapy
against HCC) in major hospitals in China and Singapore, as well as for broadening its
products pipeline to fight viral-related solid tumours and
clearance of chronic hepatitis B.
Hepatocellular carcinoma (HCC) has over 700,000 new cases every
year, the world second deadly cancer, of which 80% in Asia Pacific and 50% in China. Initial clinical trials of
LioCyx™ for late stage HCC have produced encouraging
results of good efficacy and very good safety profile.
LioCyx™ is developed by Lion TCR's scientific founder,
Prof. Antonio Bertoletti. The team
and its collaborators in Singapore
General Hospital have recently won the 2018 SingHealth Duke-NUS
Research Award 1st Prize and the Best Abstract in EASL
International Liver Congress 2018.
Dr. Victor Li, founder and CEO of
Lion TCR, said "This finance is also a recognition of the
potential, versatility, and uniqueness of Lion TCR's novel viral
specific TCR T cell technology platform and its products pipeline.
It will allow us to accelerate the completion of Phase 1/2a
clinical trial of LioCyx™ to treat relapsed HCC case
post-liver transplantation and expand the therapy clinical trials
for other indications of HCC. With a strong internal scientific
team as well as collaborators from world renowned cancer research
and medical centres in China,
Singapore and Europe, Lion TCR continues to advance its
pioneer position on engineered T cell therapy against viral related
cancer and clearance of chronic hepatitis infection".
About Lion TCR
Lion TCR is a Singapore-based
clinical stage biotech company focusing on development of
engineered T-cell immunotherapy against viral-related cancer and
chronic hepatitis B with manufacturing and clinical trial
operations in China and
Singapore. It is world's first to
develop HBV-specific TCR T cell therapy against HCC.
Over one fifth of cancer in Asia are related to infection, primary viral
infection. For instances, Nasopharyngeal carcinoma is 100% related
to EBV infection and over 90% of HCC is related to HBV infection in
China.
Lion TCR's engineer T cell technologies are exclusively licensed
initially from Agency for Science, Technology and Research
(A*STAR), Singapore (TCR-T cell
therapy developed by Prof. Antonio
Bertoletti's lab) and lately from Technical University of
Munich (CAR-T cell therapy
developed by Prof. Urlike Protzer's
lab).
For more information about Lion TCR, please visit
http://www.liontcr.com/
CONTACT:
Stephen
Lim
stephen.lim@liontcr.com
+(65) 90060086
View original
content:http://www.prnewswire.com/news-releases/lion-tcr-receives-us-20-million-to-fund-its-personalized-t-cell-therapy-clinical-trials-against-liver-cancer-300655329.html
SOURCE Lion TCR Pte Ltd